Sage Therapeutics' GAAP loss for three months 2021 was $95.764 million, down 24.4% from $126.74 million in the prior year. Revenue declined 30.8% to $1.583 billion from $2.286 billion a year earlier.
Sage Therapeutics' GAAP loss for three months 2021 was $95.764 million, down 24.4% from $126.74 million in the prior year. Revenue declined 30.8% to $1.583 billion from $2.286 billion a year earlier. 
investor.sagerx.com
English (US) 